<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296621</url>
  </required_header>
  <id_info>
    <org_study_id>P030420</org_study_id>
    <secondary_id>AOM 03 121</secondary_id>
    <nct_id>NCT00296621</nct_id>
  </id_info>
  <brief_title>Effect of Oral Glutamine on Muscle Mass and Function in Duchenne Muscular Dystrophy</brief_title>
  <acronym>MDB-GLN</acronym>
  <official_title>Efficacy Study of Oral Glutamine Supplementation in Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether long-term oral glutamine supplementation is
      effective in improving muscle mass and function in children with Duchenne muscular dystrophy
      (DMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glutamine inhibits whole body protein degradation in children with Duchenne Muscular
      Dystrophy (DMD). The effect is observed after 5 h oral glutamine administration and is also
      found when glutamine is given over a 10-day period. This multi-site national study aims to
      evaluate the functional benefit of long-term oral glutamine administration in 30 DMD children
      using a randomized double-blind placebo-controlled cross-over design. The study includes two
      4-month periods: 1) a treatment period in which the subject receives oral glutamine (0.5
      g/kg/d) and 2) a control period in which the subject receives a placebo. The order of
      treatment allocation is randomized. The two 4-month periods are separated by a 1 month
      wash-out period. The children are monitored every 2 months during period 1 (M0, M2, M4) and
      period 2 (M5, M7, M9) in the clinical investigation centres of Hospital Robert Debré in Paris
      and the CHR&amp;U de Lille, as well as the clinical research centre of the CHU de Poitiers.
      Evidence of a functional benefit would involve evaluating the administration of glutamine
      over longer periods (as early as possible following diagnosis) among severely handicapped
      children and in other chronic pathologies associated with increased muscle protein
      catabolism. In DMD, such evidence would enable children to undergo gene therapy under
      improved physical condition.

      Comparisons: Glutamine administration compared to placebo on the following outcome measures:
      walking speed on a standard course, work (kcal) and power (kcal/s) in relation to effort,
      body composition (bioelectrical impedance analysis and BIPHOTONIC absorptiometry), muscle
      mass (24-h urinary creatinine excretion), indices of protein degradation (CPK and 3-methyl
      histidine excretion) and biochemical parameters (electrolytes, fasting glucose,
      transaminases, insulin, IgfI, Igf-BPI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Anticipated">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>walking speed at 0,2,4,5,7,9 months</measure>
    <time_frame>at 0,2,4,5,7,9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>work (kcal) at 0,2,4,5,7,9 months</measure>
    <time_frame>at 0,2,4,5,7,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>power (kcal/s) at 0,2,4,5,7,9 months</measure>
    <time_frame>at 0,2,4,5,7,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-minute walk test at 0,2,4,5,7,9 months</measure>
    <time_frame>at 0,2,4,5,7,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition (bioelectrical impedance analysis) at 0,2,4,5,7,9 months</measure>
    <time_frame>at 0,2,4,5,7,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition (BIPHOTONIC absorptiometry) at 4,9 months</measure>
    <time_frame>at 4,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle mass (24-h urinary creatinine excretion) at 0,2,4,5,7,9 months</measure>
    <time_frame>at 0,2,4,5,7,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>indices of protein degradation (CPK and 3-methyl histidine excretion) at 0,2,4,5,7,9 months</measure>
    <time_frame>at 0,2,4,5,7,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical parameters (electrolytes, fasting glucose, transaminases, insulin, IgfI, Igf-BP3) at 0,2,4,5,7,9 months</measure>
    <time_frame>at 0,2,4,5,7,9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Glutamine</intervention_name>
    <description>L-Glutamine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Duchenne muscular dystrophy

          -  Able to walk &gt;170 m

          -  Absence of hepatic insufficiency

          -  Absence of renal insufficiency

        Exclusion Criteria:

          -  Dependent upon wheelchair

          -  Body weight &gt;60kg

          -  Liver failure

          -  Kidney failure

          -  Surgery scheduled during the year following the first visit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Régis Hankard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire (CHU) de Poitiers</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique, Hôpital Cardiologique, CHR&amp;U de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépato Gastro Entérologie, Hôpital Jeanne de Flandre, CHR&amp;U de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neuropédiatrie, Hôpital Roger Salengro, CHR&amp;U de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique (CIC9202), Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75935</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pédiatrie Multidisciplinaire et Nutrition de l'Enfant, Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Mok E, Eléouet-Da Violante C, Daubrosse C, Gottrand F, Rigal O, Fontan JE, Cuisset JM, Guilhot J, Hankard R. Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy. Am J Clin Nutr. 2006 Apr;83(4):823-8.</citation>
    <PMID>16600934</PMID>
  </reference>
  <reference>
    <citation>Hankard R, Mauras N, Hammond D, Haymond M, Darmaun D. Is glutamine a 'conditionally essential' amino acid in Duchenne muscular dystrophy? Clin Nutr. 1999 Dec;18(6):365-9.</citation>
    <PMID>10634922</PMID>
  </reference>
  <reference>
    <citation>Hankard RG, Hammond D, Haymond MW, Darmaun D. Oral glutamine slows down whole body protein breakdown in Duchenne muscular dystrophy. Pediatr Res. 1998 Feb;43(2):222-6.</citation>
    <PMID>9475288</PMID>
  </reference>
  <reference>
    <citation>Hankard RG, Haymond MW, Darmaun D. Effect of glutamine on leucine metabolism in humans. Am J Physiol. 1996 Oct;271(4 Pt 1):E748-54.</citation>
    <PMID>8897864</PMID>
  </reference>
  <reference>
    <citation>Hankard RG, Darmaun D, Sager BK, D'Amore D, Parsons WR, Haymond M. Response of glutamine metabolism to exogenous glutamine in humans. Am J Physiol. 1995 Oct;269(4 Pt 1):E663-70.</citation>
    <PMID>7485479</PMID>
  </reference>
  <reference>
    <citation>Mok E, Béghin L, Gachon P, Daubrosse C, Fontan JE, Cuisset JM, Gottrand F, Hankard R. Estimating body composition in children with Duchenne muscular dystrophy: comparison of bioelectrical impedance analysis and skinfold-thickness measurement. Am J Clin Nutr. 2006 Jan;83(1):65-9.</citation>
    <PMID>16400051</PMID>
  </reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <last_update_submitted>December 20, 2007</last_update_submitted>
  <last_update_submitted_qc>December 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <responsible_party>
    <name_title>Régis Hankard, MD PhD</name_title>
    <organization>CHU de Poitiers</organization>
  </responsible_party>
  <keyword>glutamine</keyword>
  <keyword>nutrition</keyword>
  <keyword>children</keyword>
  <keyword>pediatrics</keyword>
  <keyword>randomized controlled clinical trial</keyword>
  <keyword>therapy</keyword>
  <keyword>supplement</keyword>
  <keyword>oral administration</keyword>
  <keyword>handicap</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

